Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (274,448)	$ (342,994)	$ (234,632)
Adjustments to reconcile net loss to net cash used in operating activities:
Acquired IPR&D expense	66,332	87,184	0
Stock-based compensation expense	41,829	33,144	47,084
Loss on securities purchase agreement put/call	19,185	0	0
Depreciation and amortization expense	11,539	19,631	20,250
Net amortization and accretion on marketable securities	(4,959)	(14,681)	(9,596)
Non-cash lease income	(3,550)	(2,198)	(1,873)
Loss on property and equipment disposals, net	3,344	1,341	1,509
Change in fair value of contingent consideration payable	(1,706)	(3,804)	0
Impairment of long-lived assets	1,443	51,297	0
Change in fair value of success payment liabilities	831	(1,165)	(2,780)
Impairment of other investments	0	13,001	12,923
Loss (gain) on marketable equity security	30	(30)	0
Changes in operating assets and liabilities:
Prepaid expenses, other current assets and other assets	2,823	1,775	3,125
Accounts payable	(2,339)	(3,234)	1,464
Accrued liabilities and other current liabilities	(7,642)	(1,250)	(719)
Other non-current liabilities	(2,736)	(411)	(449)
Net cash used in operating activities	(150,024)	(162,394)	(163,694)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(780)	(464)	(2,686)
Sales of property and equipment	287	0	0
Purchases of marketable securities	(278,899)	(394,707)	(476,880)
Maturities of marketable securities	374,684	548,941	663,614
Acquisition of assets, net of cash acquired	(41,195)	(31,346)	0
Net cash provided by investing activities	54,097	122,424	184,048
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from securities purchase agreement equity issuance	50,000	0	0
Proceeds from exercise of stock options	42	154	306
Proceeds from employee stock purchase plan	365	1,248	1,894
Taxes paid related to net share settlement of equity awards	(1)	(76)	(457)
Net cash provided by financing activities	50,406	1,326	1,743
Net (decrease) increase in cash, cash equivalents and restricted cash	(45,521)	(38,644)	22,097
Cash, cash equivalents and restricted cash at beginning of period	107,287	145,931	123,834
Cash, cash equivalents and restricted cash at end of period	61,766	107,287	145,931
Represented by:
Cash and cash equivalents	60,181	105,597	145,647
Restricted cash	1,585	1,690	284
Total	61,766	107,287	145,931
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for amounts included in the measurement of lease liabilities	12,587	11,467	10,845
Non-cash investing and financing activities:
Equity issued for Acquisition (Note 3)	33,972	36,011	0
Securities purchase agreement put/call issuance	7,774	0	0
Equity issued for contingent consideration - ImmPACT Bio USA Inc. acquisition	5,894	0	0
Contingent consideration payable related to the purchase of the IPR&D asset on Closing Date (Note 3 & 8)	0	11,404	0
Purchases of property and equipment included in accounts payable and accrued liabilities	$ 0	$ 144	$ 29